How changing thyroid hormone levels affects blood sugar, lipids, and energy use
Impact of Thyroid Hormones on Human Glucose and Energy Metabolism
NA · University of Ulm · NCT07410637
This trial will test whether raising or lowering thyroid hormones in people with newly diagnosed Graves' disease or thyroid cancer changes blood sugar, insulin, and lipid metabolism using oral glucose tolerance tests.
Quick facts
| Phase | NA |
|---|---|
| Study type | Interventional |
| Enrollment | 60 (estimated) |
| Sex | All |
| Sponsor | University of Ulm (other) |
| Locations | 1 site (Ulm, Baden-Wurttemberg) |
| Trial ID | NCT07410637 on ClinicalTrials.gov |
What this trial studies
Researchers will compare people whose thyroid hormone levels are intentionally lowered for Graves' disease with people whose thyroid hormones are raised as part of thyroid cancer care. Oral glucose tolerance tests will be done before treatment, two weeks after starting treatment, and three months after starting treatment to track changes over time. Metabolic measures will include blood glucose, insulin secretion and sensitivity, lipid levels, resting energy expenditure, respiratory quotient, and measures of liver fat, eating, and physical activity. The goal is to clarify how clinical changes in thyroid hormone levels alter human glucose and energy metabolism.
Who should consider this trial
Good fit: Ideal candidates are adults with a new diagnosis of Graves' disease or thyroid carcinoma who can undergo an oral glucose tolerance test and attend follow-up visits at Ulm University Hospital.
Not a fit: People with diabetes, current acute infections, contraindications to an oral glucose tolerance test, or who require exogenous insulin are excluded and are unlikely to benefit from this protocol.
Why it matters
Potential benefit: If successful, the results could help clinicians tailor thyroid treatments to reduce unwanted changes in blood sugar, insulin function, and lipids.
How similar studies have performed: Most prior evidence comes from animal studies and small or conflicting human reports, so prospective human data on this exact approach are limited.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * patients with initial diagnosis of graves disease OR * patients with initial diagnosis of thyroid carcinoma Exclusion Criteria: * contraindications for oral glucose tolerance test * Diabetes mellitus * Fasting glucose level ≥ 200 mg/dL * Exogenous insulin administration with action at the time of the test * Current disease with activation of stress hormones * Post-aggressive metabolism * Acute infectious disease
Where this trial is running
Ulm, Baden-Wurttemberg
- Ulm University Hospital — Ulm, Baden-Wurttemberg, Germany (RECRUITING)
Study contacts
- Principal investigator: Martin Heni — University of Ulm
- Study coordinator: Martin Heni, Prof
- Email: martin.heni@uniklinik-ulm.de
- Phone: +4973150044505
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Graves Disease, Thyroid Cancer, thyroid hormones, glucose metabolism, lipid metabolism, graves disease, thyroid cancer, hyperthyroidism